BIGBEAR
PHARMACEUTICAL
Quizartinib specifically targets the FLT3-ITD mutant protein, blocking downstream MAPK/ERK, PI3K/AKT, and STAT5 signaling pathways, thereby inhibiting leukemia cell proliferation and inducing apoptosis.
AuthenticGuaranteeFast DeliveryPrivacy GvHD is a common and potentially life-threatening complication, occurring in approximately half of allogeneic stem cell transplants.On May 5, 2022, No···【More】
Update: 10 Apr,2026Source: BigbearViews: 100
Recently, the European Medicines Agency's Committee on Medical Products for Human Use recommended the approval of ruxolitinib (Jakafi) for the tre···【More】
Update: 10 Apr,2026Source: BigbearViews: 98
According to a press release from Incyte on April 20, the European Commission (EC) announced that it has granted marketing authorization to Opzelura 1···【More】
Update: 10 Apr,2026Source: BigbearViews: 99
.SunPharma's oral small-molecule drug Leqselvi (deuruxolitinib) is now available in the US for the treatment of adults with severe alopecia areata···【More】
Update: 10 Apr,2026Source: BigbearViews: 94
However, adherence to prescribed medication regimens directly impacts treatment efficacy and patient safety when using quizartinib. Patients should st···【More】
Update: 10 Apr,2026Source: BigbearViews: 94
Recently, the European Commission (EC) authorized VANFLYTA in combination with standard cytarabine and anthracycline induction therapy, followed by st···【More】
Update: 10 Apr,2026Source: BigbearViews: 87
According to a press release yesterday from Daiichi Sankyo Pharmaceutical Co., Ltd., VANFLYTA (quizartinib) has been launched in the United States. Th···【More】
Update: 10 Apr,2026Source: BigbearViews: 88
Daiichi Sankyo announced on July 20 that the U.S. Food and Drug Administration (FDA) has approved Vanflyta (quizartinib) in combination with standard ···【More】
Update: 09 Apr,2026Source: BigbearViews: 90
Yesterday, Daiichi Sankyo Pharmaceutical announced in a press release that the Japanese Ministry of Health, Labour and Welfare (MHLW) has approved the···【More】
Update: 09 Apr,2026Source: BigbearViews: 89
The U.S. FDA has recently accepted and granted priority review to quizartinib's New Drug Application (NDA). The NDA grant is for the treatment of ···【More】
Update: 09 Apr,2026Source: BigbearViews: 86
Copyright2024@ BIGBEAR All right reserved Bigbear | Bigbear Pharmaceutical | Bigbear Laos
